share_log

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga Real-time News ·  May 16, 2022 08:21

 

Gainers

  • Athenex (NASDAQ:ATNX) shares increased by 30.5% to $0.62 during Monday's pre-market session. The market value of their outstanding shares is at $69.1 million. As per the press release, Q1 earnings came out 4 days ago.
  • Verastem (NASDAQ:VSTM) stock rose 25.0% to $1.35. The company's market cap stands at $251.5 million.
  • Cidara Therapeutics (NASDAQ:CDTX) stock increased by 14.48% to $0.49. The company's market cap stands at $33.8 million. The company's, Q1 earnings came out 3 days ago.
  • Genocea Biosciences (NASDAQ:GNCA) shares moved upwards by 13.33% to $0.26. The company's market cap stands at $14.9 million.
  • Phio Pharma (NASDAQ:PHIO) shares increased by 13.07% to $0.8. The market value of their outstanding shares is at $10.9 million. The company's, Q1 earnings came out 2 days ago.
  • Epizyme (NASDAQ:EPZM) shares increased by 11.4% to $0.58. The market value of their outstanding shares is at $95.6 million. As per the press release, Q1 earnings came out 4 days ago.

Losers

  • Chimerix (NASDAQ:CMRX) stock decreased by 52.6% to $2.01 during Monday's pre-market session. The company's market cap stands at $175.7 million. As per the press release, Q1 earnings came out today.
  • Valneva (NASDAQ:VALN) stock fell 19.39% to $20.08. The company's market cap stands at $1.0 billion.
  • Akebia Therapeutics (NASDAQ:AKBA) shares fell 16.52% to $0.38. The market value of their outstanding shares is at $68.8 million.
  • Immix Biopharma (NASDAQ:IMMX) stock fell 15.71% to $1.1. The company's market cap stands at $15.2 million.
  • Calithera Biosciences (NASDAQ:CALA) stock declined by 15.61% to $0.19. The company's market cap stands at $21.7 million. As per the press release, Q1 earnings came out 4 days ago.
  • Surgalign Holdings (NASDAQ:SRGA) stock fell 14.29% to $0.16. The company's market cap stands at $31.0 million. The company's, Q1 earnings came out 4 days ago. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment